Author:
Coutré Steven E.,Barrientos Jacqueline C.,Brown Jennifer R.,de Vos Sven,Furman Richard R.,Keating Michael J.,Li Daniel,O’Brien Susan M.,Pagel John M.,Poleski Martin H.,Sharman Jeff P.,Yao Nai-Shun,Zelenetz Andrew D.
Subject
Cancer Research,Oncology,Hematology
Reference21 articles.
1. CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
2. ZYDELIG (idelalisib tablets). Full prescribing information, Gilead Sciences, Inc., Foster City, CA, 2014.
3. ZYDELIG (idelalisib tablets). Summary of product characteristics, Gilead Sciences International Ltd, Cambridge, UK, 2014.
4. AKT/PKB Signaling: Navigating Downstream
5. PI3K in lymphocyte development, differentiation and activation
Cited by
257 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献